Compare DexCom, Inc. (DXCM) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs NextEra Energy, Inc. — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while NextEra Energy, Inc. trades at $77.4 (market cap $161.39B). The key difference: NextEra Energy, Inc. is far larger — about 5.1× DexCom, Inc.'s market cap, and NextEra Energy, Inc. pays a 3.22% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and NextEra Energy, Inc. for 83 Days on average.
| DXCM | NEE | |
|---|---|---|
Market Cap | $31.86B | $161.39B |
Volume | 3,607,070 | 11,780,955 |
Sector | Health | Utilities |
52-Week High | $92.34 | $97.88 |
52-Week Low | $54.84 | $75.49 |
Typical Hold Time | 62 Days | 83 Days |
Enterprise Value | $31.32B | $268.72B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
NextEra Energy (NEE) trades at $77.34, up 0.36% on the day, with a bearish technical signal but strong analyst support. The stock is near a 52-week low, with key support at $76. Recent earnings show mixed results, beating in Q1 and Q2 2026 but missing in Q4 2025. The company maintains robust profitability with a 32.4% net margin and is pursuing growth through projects like the $22.3 billion Project Star energy campus.
The outlook is cautiously optimistic, with a consensus price target of $96 offering 24% upside. Risks include high debt levels and interest rate sensitivity, but strong cash flow and a 66.7% buy rating from analysts suggest long-term value. Investors should weigh growth initiatives against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
